Welcome to our dedicated page for LOBE SCIENCES news (Ticker: LOBEF), a resource for investors and traders seeking the latest updates and insights on LOBE SCIENCES stock.
Lobe Sciences Ltd. reports news as a clinical-stage biopharmaceutical company that acquires preclinical and early-stage therapeutic assets and advances them through focused subsidiaries. Its development model centers on formulation work, intellectual property protection, regulatory engagement, and program-specific funding structures.
Recurring updates include progress for Cynaptec Pharmaceuticals' L-130 program and Applied Lipid Technologies' S-100 program, including disease areas such as chronic cluster headache and sickle cell disease. Company news also covers financial results, private placements, working-capital actions, investor relations engagements, healthcare conference participation, and public-company governance changes.
Lobe Sciences (CSE:LOBE, OTCQB:LOBEF) has closed the second tranche of its non-brokered private placement of common shares at $0.085 per share. The second tranche comprised 705,882 shares for gross proceeds of $60,000, following a first tranche of 24,705,880 shares for $2,100,000 closed on August 19, 2026.
In total, the company issued 25,411,762 shares for aggregate gross proceeds of $2,160,000. According to Lobe, proceeds will fund working capital, general corporate purposes, and advancement of its S-100 drug candidate for sickle cell disease through subsidiary Applied Lipid Technologies, which has already secured the required active pharmaceutical ingredient.
Lobe Sciences (CSE: LOBE, OTCQB: LOBEF) has upsized its previously announced non-brokered private placement of common shares at $0.085 per share. The company closed a first tranche on August 19, 2026, issuing 24,705,880 shares for gross proceeds of $2,100,000. It intends to close a second tranche of 705,882 shares for approximately $60,000, bringing the total to 25,411,762 shares and $2,160,000 in gross proceeds, subject to Canadian Securities Exchange approval. Proceeds are earmarked for working capital, general corporate purposes, and advancing Lobe’s S-100 drug candidate for sickle cell disease, including funding subsidiary Applied Lipid Technologies’ work toward human clinical trials using already procured active pharmaceutical ingredient.
Lobe Sciences (OTCQB: LOBEF) announced the appointment of Dr. David Kideckel, PhD, MBA as Chief Financial Officer, effective September 1, 2026, subject to acceptance by the Canadian Securities Exchange. Current CFO Mirza Rahimani will transition to Vice President of Finance on the same date, maintaining continuity in accounting, reporting, compliance and financial operations.
According to Lobe, Dr. Kideckel brings nearly two decades of experience spanning life sciences, capital markets and corporate advisory roles, including senior positions at a large North American private investment bank, Johnson & Johnson and Alexion Pharmaceuticals. The company highlights this leadership change as support for advancing its clinical-stage pipeline, including L-130 for chronic cluster headache and S-100 for sickle cell disease.
Lobe Sciences (OTCQB: LOBEF) closed its previously announced non-brokered private placement, issuing 24,705,880 common shares at $0.085 per share for gross proceeds of approximately $2.1 million. All securities are subject to a four-month hold period under Canadian securities laws.
According to the company, net proceeds will fund working capital, general corporate purposes, and advancement of its S-100 drug candidate for sickle cell disease. A portion will be allocated to wholly owned subsidiary Applied Lipid Technologies to progress S-100 toward human clinical trials, supported by procurement of the required active pharmaceutical ingredient.
Lobe Sciences (CSE:LOBE, OTCQB:LOBEF) reported unaudited Q3 2026 results for the period ended May 31, 2026. Cash was $1.51 million with short-term investments of $3.70 million, and net working capital totaled $3.20 million.
R&D expenses for the nine months were $2.45 million, up from $0.30 million a year earlier, tied to Cynaptec’s L-130 and Applied Lipid Technologies’ S-100 programs. Cash used in operating activities for the nine months was $3.35 million, versus $1.02 million in the prior-year period. Net loss for the quarter was $4.84 million, compared with $2.64 million last year.
Directors and officers settled $1.37 million of accrued fees for 12.48 million shares at $0.11, and the company closed a $0.95 million non-brokered private placement at $0.065 per share. A further $2.10 million private placement at $0.085 per share is anticipated to close around August 19, 2026, subject to regulatory approvals.
Lobe Sciences (CSE:LOBE, OTCQB:LOBEF) announced a non-brokered private placement of 24,705,880 common shares at $0.085 per share, targeting gross proceeds of approximately $2.1 million.
According to the company, net proceeds will support cash reserves, clinical development of the S-100 molecule at subsidiary Applied Lipid Technologies, and general working capital. The financing is subject to Canadian Securities Exchange approval, and all securities will carry a four‑month hold period under Canadian securities laws.
Lobe Sciences (OTCQB:LOBEF) reported the results of its July 30, 2026 Annual General and Special Meeting, where 152,807,032 common shares (about 49.6% of outstanding shares) were represented and all resolutions were approved. Shareholders elected five directors and re-appointed Davidson & Company as auditor, with support levels around 99.8%.
Investors approved a new Long-Term Incentive Plan that cuts the maximum shares issuable under all security-based compensation from 40% to 20%, and ratified prior RSU grants. A special resolution amending constating documents, including eliminating the preferred share class, passed with 99.773% support, which management says simplifies capital structure and governance.
Management outlined a strategy of advancing pharmaceutical assets via subsidiaries and ongoing work toward a future senior exchange listing. Updates highlighted preclinical and regulatory progress for Cynaptec’s L-130 program for chronic cluster headache and Applied Lipid Therapeutics’ S-100 sickle cell disease program, including CMC work and an FDA Orphan Drug Designation application under review.
Lobe Sciences (OTCQB:LOBEF) filed its Management Information Circular for the Annual General and Special Meeting on July 30, 2026, 11:00 a.m. Vancouver time, in Vancouver with virtual Microsoft Teams access.
Shareholders will vote on directors, auditors, a new LTIP, prior RSU grants, and amendments to constating documents, and receive strategy and pipeline updates including uplisting plans and three subsidiary programs.
Lobe Sciences (OTCQB:LOBEF) settled C$1,372,761.20 of accrued management and director fees by issuing 12,749,643 common shares at C$0.11, increasing insider ownership to over 40%. The Canadian Securities Exchange accepted the issuance.
The company reported C$4.96 million in cash and short-term investments and C$2.12 million in R&D spending in the first half of fiscal 2026, reflecting active clinical development of its L-130 and S-100 programs via majority-owned subsidiaries.
Lobe Sciences (OTCQB:LOBEF) plans to settle C$1,372,761.20 of management and director fee debt by issuing 12,749,643 common shares at $0.11 per share, subject to Canadian Securities Exchange approval. The move preserves cash for operations while the company advances its L-130 and S-100 clinical programs.